Legend Biotech Corp
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type other
SEC Category Large accelerated filer
State of Incorporation Cayman Islands
Business Address 2101 COTTONTAIL LANE, SOMERSET, NJ, 08873
Mailing Address 2101 COTTONTAIL LANE, SOMERSET, NJ, 08873
Phone 732-850-5598
Fiscal Year End 1231
EIN 000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 27, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
Annual Reports
20-F March 10, 2026
- CARVYKTI's 2024 approval for second-line multiple myeloma (2LMM) significantly expands its market opportunity.
- Anticipated CARVYKTI approval in Japan by 2025 promises to unlock another major global market.
Insider Trading
SELL 1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.